16th Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC)
TBDSeattle, USA Visit the Venue to read more
16th Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC) is organized by The Metabolic Institute of America (TMIOA) and will be held during Nov 29 - Dec 01, 2018 at Los Angeles, California, United States of America.
The target audience for this medical event is cardiologists, endocrinologists, gastroenterologists, oncologists, internists, diabetologists, OBGYNs, pediatricians, dietitians, nurse practitioners, pharmacists, and any other health care professionals who are interested in insulin resistance, diabetes, obesity, cardiovascular disease, and multiple metabolic mechanisms’ effects on health and society, as well as on potential treatment and prevention. This CME Conference has been approved for a maximum of 28 AMA PRA Category 1 Credits.
Course Objectives are :
The program is designed to evaluate both the clinical and basic science aspects of diabetes, obesity, dyslipidemia and CVD, by focusing on insulin resistance, hyperinsulinemia, fat cells, the heart, the kidneys, and energy metabolism. The goal is to understand its pathophysiology, and to develop appropriate comprehensive clinical management plans.
Upon completion of this meeting, participants should be able to:
• Provide comprehensive management of diabetes, by addressing obesity, hypertension, dyslipidemia, and cardiovascular risks.
• Discuss the role of obesity in the development of cardiometabolic conditions
• Discuss the role of incretins in the management of obesity, diabetes, and prevention of CVD
• Be aware of the results of cardiovascular outcome trials and understand the potential role of SGLT2i & GLP1ra in managing Diabetes and CVD
• Evaluate the extent of macrovascular and microvascular disease in diabetes and obesity
• Address the risks of heart disease in patients with diabetes
• Explain the role of lipids, in particular low-density lipoprotien (LDL-C) and non- HDL-C, in the development of atherosclerosis
• Examine the role of PCSK9 and the newly developed monoclonal antibodies- the PCSK9 inhibitors in LDL homeostasis and on the contemporary approaches to management and prevention of CVD
• Describe contemporary approaches to congestive heart failure
• Explain the relationship of the kidney to insulin resistance, diabetes and CVD
• Explain the pathophysiology and complications of fatty liver disease and its relationship to diabetes and CVD
• Discuss the role of SGLT2i in the management of diabetes its potential role beyond glycemia and known complications.
• Evaluate bariatric surgery and newly-developed procedures, as well as devices and their effect on weight loss and hormones, and their long-term outcomes
Yehuda Handelsman, MD, FACP, FNLA, MACE Chair
Chair & Program Director, 2nd HiD & 16th Annual WCIRDC
Medical Director & Principal Investigator, Metabolic Institute of America
Chair & Founder, International Committee for Insulin Resistance
Chair & Founder, International Lipid Forum
King, George L 2.jpg
George L. King, MD
Chief Scientific Officer,
Joslin Diabetes Center
Professor of Medicine and Ophthalmology
Harvard Medical School
Richard N. Bergman, PhD
Alfred Jay Firestein Chair in Diabetes Research
Professor, Department of Biomedical Sciences, Cedars-Sinai
Director, Sports Spectacular Diabetes and Obesity Wellness and Research Center (SSDOWRC)
Professor-in-Residence, Department of Medicine, UCLA
Los Angeles, California
Samuel Klein, MD
William H. Danforth Professor of Medicine and Nutritional Science
Director, Center for Human Nutrition
Chief, Division of Geriatrics & Nutritional Science
Washington University School of Medicine
St. Louis, Missouri
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
The 16th WCIRDC will be held at the Hilton Universal City Hotel in Los Angeles, California from November 29 - December 1, 2018.
Special room rates of $214 per night are available for all WCIRDC attendees.
To book rooms at the Hilton, please go here: https://book.passkey.com/e/49638626
OR call (818) 623-1434 and reference group name: WCIRDC
Group room reservations are also available. To book a block of rooms for your group of 15 or more, please contact us at email@example.com or (818) 342-1889.
We hope to see you there!
Hilton Universal City Hotel
Address: 555 Universal Hollywood Dr, Universal City, CA 91608
Phone: (818) 506-2500
Accepted Abstracts will be published in Endocrine Practice, the official journal of AACE.
Accepted Abstracts will have a poster presentation at the meeting.
Top Abstracts will be selected for oral presentation at the meeting.
In some cases, the committee may consider Late Breaking Abstracts for oral presentation.
Abstract Submission & Topics:
Clinical aspects of insulin resistance in childhood, adolescence and/or adulthood pertaining to:
Diabetes, obesity, dyslipidemia, hypertension, cardiovascular disease, malignancy, liver disease, renal disease, gonadal dysfunction, sleep disorders such as obstructive sleep apnea.
Mechanisms of insulin resistance, inflammation, endothelial and vascular dysfunction, metabolic dysfunction of centers such as the beta cell, adipocyte, gut, and brain.
Abstracts should address either clinical or basic science aspects of insulin resistance, in fields such as diabetes, obesity, and cardiovascular disease. Investigations of overall pathophysiology and/or effects on key metabolic centers such as the beta cell, adipocyte, gut, and brain would be of interest, as would be studies of inflammation and of endothelial or other vascular dysfunction. Clinical topics may include any aspect of insulin resistance in childhood, adolescence and/or adulthood in relationship to the causation and/or natural history of obesity, diabetes, hypertension, dyslipidemia, cardiovascular disease, renal disease, gonadal dysfunction (including both PCOS and male hypogonadism), gestational diabetes, other endocrine abnormality, liver disease (NAFLD), malignancy, and sleep disorders such as obstructive sleep apnea.
The interests of the Congress include multi-hormonal aspects of obesity, incretins and other gut hormonal contributions to energy balance, and circadian rhythm as it relates to these metabolic mechanisms. Basic science studies should include those with specific relationship to insulin action and its regulation at the cellular, organ, or whole body level.
To demonstrate their conformity to this guideline, authors are encouraged to include a brief clarification of the relationship of their topic to insulin resistance and/or to the above metabolic processes.
Scientific materials presented at the 16th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (2018) must not have been published or presented prior to November 29, 2018, other than in abstract form.
All abstracts must be submitted electronically on a Microsoft Word document of no more than 250 words. Graphs are allowed not to exceed 8.5” X 11” word document (No PDF documents will be accepted, or any submissions by fax or mail.) For sample formatting, please click here.
All materials must arrive on or before the abstract deadline noted above.
Notification for acceptance will be e-mailed as soon as the committee accepts the abstract.
Authorship on multiple abstracts is permitted.
All submitted materials will be graded by the scientific planning committee, The International Committee for Insulin Resistance.
Abstracts may be submitted for poster presentation. If selected for poster presentation, the author is required to register for the Congress and to be present during the poster sessions. Awards will be given for the highest-ranking abstracts. The award levels are: Gold, Silver, Bronze, and honorable mention. The authors of the winning abstracts will orally present their research findings during the Plenary Sessions in a ten minute presentation, to be followed by a five minute period of discussion.
If selected for oral presentation, an author is required to register for the Congress and to be prepared for the oral presentation with a PowerPoint presentation. Abstracts must be accompanied by a statement from the authors agreeing that, if chosen, they will prepare a poster presentation, and that, if awarded a high ranking, they will prepare an oral presentation.
Abstracts will be published in: Endocrine Practice.Editor-in-Chief – Derek Leroith, MD, PhD “Endocrine Practice is a peer-reviewed journal published six times a year, and is the official journal of the American Association of Clinical Endocrinologists (AACE). The first issue of Endocrine Practice was published in 1995. The primary mission of Endocrine Practice is to enhance the health care of patients with endocrine diseases through continuing education of practicing endocrinologists.”
Abstract submission deadline 2018-10-22
Contact No.: 818-342-1889
Contact No.: 818-342-1889